This Week in Oncology: Real-World NSCLC Care and AACR 2026 Updates The American Association for Cancer Research (AACR) Annual Meeting 2026, held from April 17 to 22 in San Diego, California, served as a pivotal forum for advancing cancer science and sharing the latest breakthroughs in oncology research. As the premier gathering of the cancer community, the meeting highlighted critical developments in non-small cell lung cancer (NSCLC) care, spanning real-world treatment patterns, basic science discoveries, and translational advances. Real-World Insights into NSCLC Treatment Patterns Discussions at the meeting emphasized the growing importance of real-world evidence in shaping NSCLC management. Experts examined how treatment decisions are made in community oncology settings, including the use of biomarker testing, immunotherapy combinations, and targeted therapies across diverse patient populations. These analyses aim to bridge the gap between clinical trial results and everyday practice, identifying barriers to optimal care and opportunities for improving outcomes. Basic and Translational Science Highlights Sessions dedicated to basic and translational science showcased novel mechanisms driving NSCLC progression and resistance. Researchers presented findings on tumor microenvironment interactions, genomic alterations, and innovative therapeutic targets. Notably, work highlighted the role of specific signaling pathways in immune evasion and explored strategies to enhance response rates to existing treatments through rational drug combinations. Live Updates from the Meeting Floor Throughout the week, attendees received real-time coverage of key presentations and discussions. On Monday, April 20, sessions focused on emerging data from early-phase clinical trials, updates on adjuvant and neoadjuvant approaches, and ongoing efforts to address disparities in lung cancer care. The meeting also featured dedicated programming for early-career investigators, oncology nurses, and patient advocates, fostering broad engagement across the cancer research ecosystem. Looking Ahead The AACR Annual Meeting 2026 reinforced the necessity of integrating scientific discovery with real-world application to accelerate progress against NSCLC. By uniting laboratory investigators, clinicians, and public health experts, the meeting continues to drive innovation aimed at improving survival and quality of life for people living with lung cancer worldwide. For ongoing coverage of developments from the AACR Annual Meeting and advances in oncology, trusted sources provide timely, evidence-based updates to support informed decision-making in cancer care and research.
61